Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleNasdaq· April 9, 2026

Bitcoin's Scariest Risk Just Became More Likely to Happen. Should You Sell It?

View original at nasdaq.com
Bitcoin's Scariest Risk Just Became More Likely to Happen. Should You Sell It? Key Points Bitcoin is secured by encryption. That encryption is thought to be very burdensome to break with normal computers…
Opening lines of the source · Nasdaq · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Protocol upgrades will almost certainly arrive before any quantum machine can exploit the vulnerability for long-term investors

    60% confidence
  • A full migration to quantum-resistant cryptography for Bitcoin could take about seven years

    60% confidence
  • The encryption-breaking risk posed by quantum computers wouldn't pose an actual threat for approximately 10 years (prior to Google's new research)

    60% confidence
  • If you need the money within five years, this new paper is a reason to temper your Bitcoin allocation

    60% confidence
  • Stock Advisor's total average return is 946% compared to 190% for the S&P 500

    60% confidence
  • Bitcoin was not identified as one of the 10 best stocks for investors to buy now

    60% confidence
  • The quantum threat window just shrank from a comfortable decade to perhaps five to seven years

    60% confidence
  • Bitcoin's encryption can be cracked within minutes by an optimized quantum computer that needs 20X fewer physical qubits than prior estimates

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com